#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab

#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab

292696

#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab

A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational therapy for Alzheimer’s disease in patients who took part in its previous clinical studies. The trial’s design was described by Carmen Castrillo-Viguera, a medical director at Biogen, in the poster “EMBARK: A Phase 3b, Open-Label, Single-Arm, Safety Study to Evaluate the Long-Term Safety and Efficacy of Aducanumab in Eligible Participants With Alzheimer’s Disease.” The poster was presented…

You must be logged in to read/download the full post.